Literature DB >> 23831020

Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells.

Liang Yu1, Yan-sheng Su, Jie Zhao, He Wang, Wei Li.   

Abstract

Epigenetic silencing mechanisms play an important role in chemoresistance of human cancer. Here we report the upregulated expression of metastasis-associated protein 1 (MTA1), a component of the nucleosome remodeling deacetylation (NuRD) complex, in chemoresistant prostate cancer (PCa). MTA1 knockdown in PC-3 cells inhibited cell proliferation and enhanced docetaxel (DTX)-induced cell death. Conversely, overexpression of MTA1 promotes DTX chemoresistance in PC-3 cells. MTA1 acted as a potent corepressor of the nuclear receptor NR4A1 transcription by interacting with histone deacetylase 2 (HDAC2). These findings suggest that MTA1 may serve as a novel DTX-resistance promoter in PC-3 cells.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemoresistance; Metastasis-associated protein 1 (MTA1); Nucleosome remodeling deacetylation (NuRD) complex; Prostate cancer (PCa)

Mesh:

Substances:

Year:  2013        PMID: 23831020     DOI: 10.1016/j.febslet.2013.06.029

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Cytoplasmic translocation of MTA1 coregulator promotes de-repression of SGK1 transcription in hypoxic cancer cells.

Authors:  H Marzook; S Deivendran; B George; G Reshmi; T R Santhoshkumar; R Kumar; M R Pillai
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

Review 2.  Role of MTA1 in cancer progression and metastasis.

Authors:  Nirmalya Sen; Bin Gui; Rakesh Kumar
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

Review 3.  MTA family of proteins in DNA damage response: mechanistic insights and potential applications.

Authors:  Da-Qiang Li; Yinlong Yang; Rakesh Kumar
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

Review 4.  Structure, expression and functions of MTA genes.

Authors:  Rakesh Kumar; Rui-An Wang
Journal:  Gene       Date:  2016-02-09       Impact factor: 3.688

5.  microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1).

Authors:  Guanlin Wu; Jian Wang; Guojun Chen; Xing Zhao
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 6.  Epigenomic regulation of oncogenesis by chromatin remodeling.

Authors:  R Kumar; D-Q Li; S Müller; S Knapp
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

7.  Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor.

Authors:  Liliya Tyutyunyk-Massey; Yilun Sun; Nga Dao; Hannah Ngo; Mallika Dammalapati; Ashish Vaidyanathan; Manjulata Singh; Syed Haqqani; Joshua Haueis; Ryan Finnegan; Xiaoyan Deng; Steve E Kirberger; Paula D Bos; Dipankar Bandyopadhyay; William C K Pomerantz; Yves Pommier; David A Gewirtz; Joseph W Landry
Journal:  Mol Cancer Res       Date:  2021-04-02       Impact factor: 6.333

8.  Orphan nuclear receptor Nur77 Inhibits Oxidized LDL-induced differentiation of RAW264.7 murine macrophage cell line into dendritic like cells.

Authors:  Liu-Hua Hu; Ying Yu; Shu-Xuan Jin; Peng Nie; Zhao-Hua Cai; Ming-Li Cui; Shi-Qun Sun; Hua Xiao; Qin Shao; Ling-Hong Shen; Ben He
Journal:  BMC Immunol       Date:  2014-11-29       Impact factor: 3.615

9.  miR-1271 inhibits ERα expression and confers letrozole resistance in breast cancer.

Authors:  Tao Yu; Hai-Ru Yu; Jia-Yi Sun; Zhao Zhao; Shuang Li; Xin-Feng Zhang; Zhi-Xuan Liao; Ming-Ke Cui; Juan Li; Chan Li; Qiang Zhang
Journal:  Oncotarget       Date:  2017-11-09

10.  Overexpression of NR4A1 is associated with tumor recurrence and poor survival in non-small-cell lung carcinoma.

Authors:  Bing Zhu; Jian-Ru Yang; Yang Jia; Pei Zhang; Lin Shen; Xiao-Long Li; Jing Li; Bing Wang
Journal:  Oncotarget       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.